pioglitazone has been researched along with Depression in 13 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed at investigating the therapeutic effect and mechanism of pioglitazone metformin complex preparation (PM) in polycystic ovary syndrome (PCOS) comorbid psychological distress." | 9.34 | Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study. ( Guo, QJ; Hu, YY; Huang, Q; Huo, CL; Shan, J; Song, JY; Wang, CQ; Xu, YF; Yu, CQ; Zhou, H, 2020) |
| "38 outpatients with bipolar disorder and current major depressive episode were randomized to pioglitazone (15-45 mg/day) or placebo." | 9.30 | Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. ( Aftab, A; Brownrigg, B; Calabrese, JR; Conroy, C; D'Arcangelo, N; Ganocy, SJ; Gao, K; Goto, T; Han, H; Kemp, DE; Schinagle, M; Serrano, MB; Woods, N, 2019) |
| "This study showed that pioglitazone could be a tolerable and effective adjunctive therapy for improving depressive symptoms in bipolar disorder without type 2 diabetes or metabolic syndrome." | 9.20 | Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. ( Akhondzadeh, S; Arbabi, M; Farokhnia, M; Ghaleiha, A; Hassanzadeh, E; Salimi, S; Sorayani, M; Zeinoddini, A, 2015) |
| "Insulin resistance has been identified as the key mechanism linking depression and diabetes." | 5.46 | Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress. ( Li, YC; Li, YJ; Qiao, JY; Shen, JD; Wei, Y, 2017) |
| "This study aimed at investigating the therapeutic effect and mechanism of pioglitazone metformin complex preparation (PM) in polycystic ovary syndrome (PCOS) comorbid psychological distress." | 5.34 | Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study. ( Guo, QJ; Hu, YY; Huang, Q; Huo, CL; Shan, J; Song, JY; Wang, CQ; Xu, YF; Yu, CQ; Zhou, H, 2020) |
| "38 outpatients with bipolar disorder and current major depressive episode were randomized to pioglitazone (15-45 mg/day) or placebo." | 5.30 | Double-blind, placebo-controlled trial of pioglitazone for bipolar depression. ( Aftab, A; Brownrigg, B; Calabrese, JR; Conroy, C; D'Arcangelo, N; Ganocy, SJ; Gao, K; Goto, T; Han, H; Kemp, DE; Schinagle, M; Serrano, MB; Woods, N, 2019) |
| "This study showed that pioglitazone could be a tolerable and effective adjunctive therapy for improving depressive symptoms in bipolar disorder without type 2 diabetes or metabolic syndrome." | 5.20 | Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. ( Akhondzadeh, S; Arbabi, M; Farokhnia, M; Ghaleiha, A; Hassanzadeh, E; Salimi, S; Sorayani, M; Zeinoddini, A, 2015) |
| " Continued use of metformin and combinations of drugs including metformin were associated with decreased rates of incident depression." | 3.96 | Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study. ( Berk, M; Ekstrøm, CT; Gerds, TA; Kessing, LV; Knop, FK; Rytgaard, HC, 2020) |
| " However, there is no published report on the effect of pioglitazone as an antidepressant in the treatment of depression induced by neuropathic pain with CCI in rats." | 3.85 | Possible modulation of PPAR-γ cascade against depression caused by neuropathic pain in rats. ( Deshmukh, VR; Garg, S; Prasoon, P, 2017) |
| "Atorvastatin is a synthetic and lipophilic statin which has been reported to have a positive role in reducing depression." | 3.80 | Antidepressant-like effect of atorvastatin in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. ( Dehpour, A; Jahanabadi, S; Javadi, S; Khoshnoodi, M; Mehr, SE; Shafaroodi, H; Shahsavarian, A; Shamsaee, J, 2014) |
| "Depression is a common comorbidity in diabetes but conventional antidepressant treatments do not consistently improve outcomes." | 2.58 | Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials. ( Hopkins, CWP; Ismail, K; Moulton, CD; Stahl, D, 2018) |
| "Insulin resistance has been identified as the key mechanism linking depression and diabetes." | 1.46 | Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress. ( Li, YC; Li, YJ; Qiao, JY; Shen, JD; Wei, Y, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, QJ | 1 |
| Shan, J | 1 |
| Xu, YF | 1 |
| Hu, YY | 1 |
| Huo, CL | 1 |
| Song, JY | 1 |
| Wang, CQ | 1 |
| Zhou, H | 1 |
| Yu, CQ | 1 |
| Huang, Q | 1 |
| Qin, X | 1 |
| Wang, W | 1 |
| Wu, H | 1 |
| Liu, D | 1 |
| Wang, R | 1 |
| Xu, J | 1 |
| Jiang, H | 1 |
| Pan, F | 1 |
| Kessing, LV | 1 |
| Rytgaard, HC | 1 |
| Ekstrøm, CT | 1 |
| Knop, FK | 1 |
| Berk, M | 1 |
| Gerds, TA | 1 |
| Lam, YY | 1 |
| Tsai, SF | 1 |
| Chen, PC | 1 |
| Kuo, YM | 1 |
| Chen, YW | 1 |
| Shen, JD | 2 |
| Wei, Y | 1 |
| Li, YJ | 1 |
| Qiao, JY | 1 |
| Li, YC | 2 |
| Liao, L | 1 |
| Zhang, XD | 1 |
| Li, J | 1 |
| Zhang, ZW | 1 |
| Yang, CC | 1 |
| Rao, CL | 1 |
| Zhou, CJ | 1 |
| Zeng, L | 1 |
| Zhao, LB | 1 |
| Fang, L | 1 |
| Yang, DY | 1 |
| Xie, P | 1 |
| Garg, S | 1 |
| Deshmukh, VR | 1 |
| Prasoon, P | 1 |
| Bonato, JM | 1 |
| Bassani, TB | 1 |
| Milani, H | 1 |
| Vital, MABF | 1 |
| de Oliveira, RMW | 1 |
| Moulton, CD | 1 |
| Hopkins, CWP | 1 |
| Ismail, K | 1 |
| Stahl, D | 1 |
| Aftab, A | 1 |
| Kemp, DE | 1 |
| Ganocy, SJ | 1 |
| Schinagle, M | 1 |
| Conroy, C | 1 |
| Brownrigg, B | 1 |
| D'Arcangelo, N | 1 |
| Goto, T | 1 |
| Woods, N | 1 |
| Serrano, MB | 1 |
| Han, H | 1 |
| Calabrese, JR | 1 |
| Gao, K | 1 |
| Shahsavarian, A | 1 |
| Javadi, S | 1 |
| Jahanabadi, S | 1 |
| Khoshnoodi, M | 1 |
| Shamsaee, J | 1 |
| Shafaroodi, H | 1 |
| Mehr, SE | 1 |
| Dehpour, A | 1 |
| Zeinoddini, A | 1 |
| Sorayani, M | 1 |
| Hassanzadeh, E | 1 |
| Arbabi, M | 1 |
| Farokhnia, M | 1 |
| Salimi, S | 1 |
| Ghaleiha, A | 1 |
| Akhondzadeh, S | 1 |
| Liu, YM | 1 |
| Chen, JJ | 1 |
| Pei, YY | 1 |
| Fang, XY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Placebo-Controlled Trial of Pioglitazone for Bipolar Depression[NCT01717040] | Phase 4 | 37 participants (Actual) | Interventional | 2012-09-30 | Terminated (stopped due to The study ended early due to budgetary issues) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) is designed to assess the severity of depressive symptoms. Total scores can range from 0 to 84 with higher scores indicating a higher severity of depressive symptoms (NCT01717040)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 31.4 |
| Placebo | 24.3 |
1 review available for pioglitazone and Depression
| Article | Year |
|---|---|
Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.
Topics: Adult; Antidepressive Agents; Blood Glucose; Clinical Trials as Topic; Depression; Diabetes Mellitus | 2018 |
3 trials available for pioglitazone and Depression
| Article | Year |
|---|---|
Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study.
Topics: Adult; Anxiety; Comorbidity; Depression; Female; Humans; Inflammasomes; Metformin; NLR Family, Pyrin | 2020 |
Double-blind, placebo-controlled trial of pioglitazone for bipolar depression.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Depression; | 2019 |
Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Combined Modality Therapy; Depression; Double- | 2015 |
9 other studies available for pioglitazone and Depression
| Article | Year |
|---|---|
PPARγ-mediated microglial activation phenotype is involved in depressive-like behaviors and neuroinflammation in stressed C57BL/6J and ob/ob mice.
Topics: Animals; Behavior, Animal; Cognitive Dysfunction; Cytokines; Depression; Disease Models, Animal; Hip | 2020 |
Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Denmark; Depression; Diabetes Mellitus, Type | 2020 |
Pioglitazone rescues high-fat diet-induced depression-like phenotypes and hippocampal astrocytic deficits in mice.
Topics: Animals; Anxiety; Astrocytes; Blood Glucose; Depression; Diet, High-Fat; Hippocampus; Hypoglycemic A | 2021 |
Curcumin reverses the depressive-like behavior and insulin resistance induced by chronic mild stress.
Topics: Animals; Behavior, Animal; Blood Glucose; Corticosterone; Curcumin; Depression; Disease Models, Anim | 2017 |
Pioglitazone attenuates lipopolysaccharide-induced depression-like behaviors, modulates NF-κB/IL-6/STAT3, CREB/BDNF pathways and central serotonergic neurotransmission in mice.
Topics: Anilides; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cyclic | 2017 |
Possible modulation of PPAR-γ cascade against depression caused by neuropathic pain in rats.
Topics: Animals; Brain; Catalase; Depression; Dose-Response Relationship, Drug; Glutathione; Immobility Resp | 2017 |
Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Male; Mortality; Ne | 2018 |
Antidepressant-like effect of atorvastatin in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway.
Topics: Anilides; Animals; Antidepressive Agents; Atorvastatin; Depression; Heptanoic Acids; Hydroxymethylgl | 2014 |
Resveratrol Ameliorates the Depressive-Like Behaviors and Metabolic Abnormalities Induced by Chronic Corticosterone Injection.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Glucose; Body Weight; Corticosterone; Depres | 2016 |